At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 212 target
Drug / intervention
PD-1 blocking antibody +2 moredrug
Likely dose
PD-1 blocking antibody 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PD-1 Antibody Combined With Chemoradiotheapy vs. Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients: a Multicenter, Randomised Controlled, Phase III Clinical Trial
In Brief
A Phase 3 clinical trial evaluating PD-1 blocking antibody, GP, and 1 other intervention for Recurrent Nasopharyngeal Carcinoma. Currently recruiting, targeting 212 participants across 12 sites.
Detailed Summary
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Nasopharyngeal Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 3Recruiting
20192020202120222023202420252026202720282029
First PostedApr 2019
Enrollment StartMar 2020
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2028
First PostedApr 9, 2019
Enrollment StartMar 1, 2020
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 6.8 yearsPosted 7.2 years agoPrimary completion in 5 months
Interventions
PD-1 blocking antibodydrug
Toripalimab 240mg, D1, every 3 weeks per cycle
GPdrug
Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
IMRTradiation
IMRT 60-66Gy, 1.8-2.0Gy/f/day